Education
About Us
Working with TipRanks
Follow Us
Acurx Pharmaceuticals (ACXP)
NASDAQ:ACXP
Top Page
Acurx Pharmaceuticals
(NASDAQ:ACXP)
Rating:39Underperform
Price Target:―
Positive Factors
Clinical Trials
Ibezapolstat previously exhibited promising clinical efficacy in Phase 2 trials and is preparing to enter key late-stage Phase 3 studies.
Financial Support
The company secured a $12M equity line of credit, which is expected to aid in developing ibezapolstat for Phase 3 trials.
Regulatory Progress
Received positive regulatory guidance from EU regulators for Phase 3.
Negative Factors
Clinical Trial Risks
Risks to the investment thesis and target price include failure or equivocal data in the Phase 3 trials of ibezapolstat.
Funding Needs
There needs to be a substantial capital raise and/or other funding resources to initiate a Phase 3 program.
Valuation Concerns
A combination of macro- and micro-factors have contributed to significant pullbacks in valuations, including ACXP shares which are at an all-time low.
Acurx Pharmaceuticals (ACXP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.39M
Dividend YieldN/A
Average Volume (3M)162.74K
Price to Earnings (P/E)―
Beta (1Y)0.53
Revenue GrowthN/A
EPS Growth23.65%
CountryUS
Employees4
SectorHealthcare
Sector Strength40
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.11
Shares Outstanding23,481,606
10 Day Avg. Volume271,894
30 Day Avg. Volume162,743
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)9.97
Price to Sales (P/S)0.00
P/FCF Ratio-0.78
Enterprise Value/Market Cap0.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.13
Forecast
1Y Price Target
$4.83Price Target Upside1107.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Acurx Pharmaceuticals Business Overview & Revenue Model
Company DescriptionAcurx Pharmaceuticals (ACXP) is a clinical-stage biopharmaceutical company focused on developing new antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, the Centers for Disease Control and Prevention, and the Food and Drug Administration. The company's lead product candidate, ibezapolstat, is designed to address the growing challenge of antibiotic resistance, specifically targeting Clostridioides difficile infections. Acurx is committed to advancing its pipeline of novel antibiotic compounds to meet the critical need for new treatments in infectious disease care.
How the Company Makes MoneyAcurx Pharmaceuticals makes money primarily through the development and commercialization of its proprietary antibiotic compounds. As a clinical-stage company, its revenue model includes potential future sales of its lead product candidate, ibezapolstat, once it successfully completes clinical trials and receives regulatory approval. Additionally, Acurx may secure revenue through partnerships, licensing agreements, and collaborations with other pharmaceutical companies for the development and commercialization of its pipeline products. These partnerships could involve upfront payments, milestone payments, and royalties on sales. The company's earnings are also influenced by research grants and funding from governmental or non-governmental organizations interested in combating antibiotic-resistant infections.
Acurx Pharmaceuticals Financial Statement Overview
Summary
Acurx Pharmaceuticals exhibits characteristics typical of early-stage biotech firms, such as no revenue and ongoing net losses. However, the absence of debt and ability to secure financing are positive aspects, though risks from cash outflows remain.Income Statement
Acurx Pharmaceuticals has consistently reported zero revenue over the years, indicating that it might still be in the development phase typical for many biotech companies. The company has incurred significant net losses, which is expected given the lack of revenue and high costs associated with R&D in this industry. However, the absence of revenue sources is a key concern.10
Very Negative
Balance Sheet
The company's balance sheet shows no debt, which indicates conservative financial management and lowers financial risk. However, the low equity ratio and consistent equity erosion due to net losses are concerning. The company has managed to maintain a positive equity position, though it has decreased over the years.35
Negative
Cash Flow
Acurx Pharmaceuticals is experiencing negative operating cash flows due to ongoing net losses, common for biotech firms without a marketable product yet. However, they have been able to secure financing to mitigate cash outflows, which is crucial for their operations. The lack of free cash flow growth is a significant downside.25
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | EBIT |
| 0.00 | -14.58M | -12.09M | -12.88M | -4.60M | EBITDA |
| -14.10M | 0.00 | -12.09M | 0.00 | -4.60M | Net Income Common Stockholders |
| -14.10B | -14.58M | -12.09M | -12.68M | -4.60M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 3.71M | 7.47M | 9.11M | 12.96M | 3.18M | Total Assets |
| 3.86M | 7.71M | 9.38M | 13.25M | 3.22M | Total Debt |
| 0.00 | 0.00 | 0.00 | 0.00 | 66.50K | Net Debt |
| -3.71M | -7.47M | -9.11M | -12.96M | -3.11M | Total Liabilities |
| 3.24M | 3.04M | 2.06M | 843.91K | 522.43K | Stockholders Equity |
| 615.12M | 4.67M | 7.32M | 12.41M | 2.70M |
| Cash Flow | Free Cash Flow | |||
| -10.38M | -9.80M | -7.54M | -5.01M | -3.35M | Operating Cash Flow |
| -10.38M | -9.80M | -7.54M | -5.01M | -3.35M | Investing Cash Flow |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Financing Cash Flow |
| 6.62M | 8.16M | 3.70M | 14.80M | 4.04M |
Acurx Pharmaceuticals Technical Analysis
Positive
0.40
Price Trends
0.39
Positive
0.56
Negative
1.14
Negative
Market Momentum
>-0.01
Negative
51.34
Neutral
47.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACXP, the sentiment is Positive. The current price of 0.4 is above the 20-day moving average (MA) of 0.39, above the 50-day MA of 0.39, and below the 200-day MA of 1.14, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 51.34 is Neutral, neither overbought nor oversold. The STOCH value of 47.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACXP.
Acurx Pharmaceuticals Risk Analysis
Acurx Pharmaceuticals disclosed 54 risk factors in its most recent earnings report. Acurx Pharmaceuticals reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Acurx Pharmaceuticals Peers Comparison
Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Performance Comparison
ACXP
Acurx Pharmaceuticals
0.39
-2.12
-84.46%
NURO
Neurometrix
4.58
0.60
15.08%
LYRA
Lyra Therapeutics
0.09
-0.24
-72.73%
Acurx Pharmaceuticals Earnings Call Summary
Earnings Call Date:May 13, 2025
(Q1-2025)
| % Change Since: 0.00%|
Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant scientific and regulatory progress, including positive EMA guidance and groundbreaking publications, which bolster the company's prospects. However, funding challenges and financial dependency on external sources pose risks to future clinical developments.Q1-2025 Updates
Positive Updates
Successful Direct Offerings
The company closed a $2.5 million registered direct offering in January and a $1.1 million registered direct offering in March, providing crucial funds for operations.
Positive Regulatory Guidance
Received positive regulatory guidance from the European Medicines Agency for the ibezapolstat Phase 3 clinical trial program, aligning with the FDA on key aspects.
Scientific Advancements
New publications in the Journal of Antimicrobial Agents and Chemotherapeutics highlighted the microbiome restorative potential of ibezapolstat and its selective antibacterial activity.
Patent Milestones
Secured new patents in Japan and India for DNA pol IIIC inhibitors, expiring in 2039, strengthening the ACX-375 pre-clinical antibiotic program.
Significant Reduction in Net Loss
Net loss decreased to $2.1 million from $4.4 million year-over-year, showing improved financial management despite ongoing R&D expenditures.
Publication Acceptance
Phase 2 clinical trial data accepted for publication in Lancet Microbe, showcasing ibezapolstat's high clinical cure rates and safety profile.
Negative Updates
Funding Challenges for Phase 3 Trials
Despite various funding initiatives, the company has not yet secured the necessary funds to commence the Phase 3 program for ibezapolstat.
Decreased R&D and G&A Expenses
R&D expenses decreased by $1 million due to reduced manufacturing and consulting costs, and G&A expenses decreased by $1.2 million, indicating possible limitations in ongoing projects.
Dependence on External Funding
The company continues to be heavily reliant on external funding and equity lines, indicating potential cash flow vulnerabilities.
Company Guidance
During the conference call on May 13, 2025, Acurx Pharmaceuticals provided guidance on several key metrics and future plans. The company reported a cash balance of $4.6 million as of March 31, 2025, compared to $3.7 million at the end of 2024, largely due to raising approximately $3.6 million through two registered direct offerings. Research and development expenses decreased to $0.6 million for the first quarter of 2025 from $1.6 million in the previous year, primarily due to decreased manufacturing and consulting costs. General and administrative expenses also dropped to $1.6 million from $2.8 million, attributed to reduced professional fees and share-based compensation costs. The company reported a net loss of $2.1 million, or $0.11 per diluted share, down from a net loss of $4.4 million, or $0.28 per diluted share, in the same period the previous year. Looking ahead, Acurx plans to continue exploring funding opportunities for its Phase 3 ibezapolstat clinical trial program and expects to maintain reduced operating expenses until the trial commences.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.